AU2018283781B2 - Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus - Google Patents

Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus Download PDF

Info

Publication number
AU2018283781B2
AU2018283781B2 AU2018283781A AU2018283781A AU2018283781B2 AU 2018283781 B2 AU2018283781 B2 AU 2018283781B2 AU 2018283781 A AU2018283781 A AU 2018283781A AU 2018283781 A AU2018283781 A AU 2018283781A AU 2018283781 B2 AU2018283781 B2 AU 2018283781B2
Authority
AU
Australia
Prior art keywords
cardiovascular
disease
patient
history
canagliflozin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018283781A
Other languages
English (en)
Other versions
AU2018283781A1 (en
Inventor
Norman R. Rosenthal
Douglas K. Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2018283781A1 publication Critical patent/AU2018283781A1/en
Application granted granted Critical
Publication of AU2018283781B2 publication Critical patent/AU2018283781B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018283781A 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus Active AU2018283781B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
US62/518,547 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Publications (2)

Publication Number Publication Date
AU2018283781A1 AU2018283781A1 (en) 2019-12-19
AU2018283781B2 true AU2018283781B2 (en) 2023-09-28

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018283781A Active AU2018283781B2 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus

Country Status (15)

Country Link
US (2) US20180353470A1 (enExample)
EP (1) EP3638250A1 (enExample)
JP (2) JP2020523408A (enExample)
KR (1) KR20200014406A (enExample)
CN (1) CN110740735A (enExample)
AU (1) AU2018283781B2 (enExample)
BR (1) BR112019026120A2 (enExample)
CA (1) CA3066874A1 (enExample)
CO (1) CO2019013940A2 (enExample)
EA (1) EA202090028A1 (enExample)
IL (1) IL271100A (enExample)
MX (1) MX2019014988A (enExample)
TW (1) TWI835735B (enExample)
UA (1) UA127987C2 (enExample)
WO (1) WO2018229630A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI827184B (zh) * 2021-08-03 2023-12-21 國立政治大學 第2型糖尿病併發症的風險評估系統與方法
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161918A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Therapeutic uses of empagliflozin
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514756B1 (en) 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
DK2385374T4 (en) * 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
CN102985075A (zh) * 2010-05-11 2013-03-20 田边三菱制药株式会社 含卡纳格列净的片剂
CA2938406A1 (en) * 2014-01-31 2015-08-06 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161918A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Therapeutic uses of empagliflozin
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "CANVAS-CANagliflozin cardioVascular Assessment Study (CANVAS)", 15 December 2009 (2009-12-15), XP002784710, URL:https://clinicaltrials.gov/ct2/show/study/NCT01032629 *
GHOSH RAKTIM KUMAR ET AL: "Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 212,29 - 36, *
NIKI KATSIKI ET AL: "Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management", CURRENT PHARMACEUTICAL DESIGN, vol. 23, no. 10, 12 May 2017 (2017-05-12), NL, pages 1522 - 1532, *
ROSENTHAL N ET AL: "Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1358, no. 1, pages 28 - 43. *

Also Published As

Publication number Publication date
IL271100A (en) 2020-01-30
KR20200014406A (ko) 2020-02-10
EP3638250A1 (en) 2020-04-22
TWI835735B (zh) 2024-03-21
US20210000792A1 (en) 2021-01-07
US20180353470A1 (en) 2018-12-13
CO2019013940A2 (es) 2020-01-17
JP2020523408A (ja) 2020-08-06
AU2018283781A1 (en) 2019-12-19
WO2018229630A1 (en) 2018-12-20
CA3066874A1 (en) 2018-12-20
CN110740735A (zh) 2020-01-31
JP2023113644A (ja) 2023-08-16
UA127987C2 (uk) 2024-03-06
TW201904584A (zh) 2019-02-01
EA202090028A1 (ru) 2020-04-03
BR112019026120A2 (pt) 2020-07-07
MX2019014988A (es) 2020-08-06

Similar Documents

Publication Publication Date Title
Sakai et al. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction―novel prospective cohort study―
JP2019508453A (ja) エンパグリフロジンを含む医薬組成物及びその使用
RU2768283C2 (ru) Семаглутид при сердечно-сосудистых состояниях
Janez et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
KR20240043778A (ko) 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
JP2023113644A (ja) ２型糖尿病の患者における心血管イベントの低減又は予防方法
Seoudy et al. Gliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes
AU2013241776B2 (en) Basal insulin therapy
Lehrke et al. Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: analysis of pooled events from 19 clinical trials
Sosale et al. A prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: real world evidence from clinical practice in India
Siddiqui et al. A review of sotagliflozin: The first dual SGLT-1/2 inhibitor
CN102858155A (zh) 使用双醋瑞因作为糖尿病的辅助治疗的方法
Najmutdinova et al. The application of insulin analogues in the treatment of type 2 diabetes mellitus: the focus on the cardio protection
JPWO2018229630A5 (enExample)
Roy Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report
HK40021204A (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
US20250360091A1 (en) Combination of sglt2 inhibitor and menthol and use thereof in treatment of heart disease
CA2725209C (en) Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
Oommen et al. Droxidopa for hypotension of different etiologies: two case reports
WO2025233434A1 (en) Effect of intravenous ferric carboxymaltose on exercise capacity in symptomatic patients with heart failure and a preserved ejection fraction with iron deficiency with and without anaemia
Hiremath Handbook Of Perioperative Care Of Adult Diabetes Patients: Diabetes Care–Before, During And After Surgery
Al-Harbi An open-label, uncontrolled study to evaluate the effect of verapamil on glycaemic control in type 2 diabetes mellitus patients with hypertension
Kavadi Role of Sotagliflozin in Managing Heart Failure in Diabetes
Yesilyurt et al. The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes
Imprialos et al. SGLT-2 inhibitors and cardiovascular risk: the beginning of a new therapeutic era in diabetes mellitus?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)